{
    "organizations": [],
    "uuid": "01ed72bc7b04775e6c3d9b27ca9bf37155cb4d19",
    "author": "",
    "url": "https://www.reuters.com/article/brief-ironwood-pharmaceuticals-reports-q/brief-ironwood-pharmaceuticals-reports-q1-loss-per-share-of-0-29-idUSASC09YKC",
    "ord_in_thread": 0,
    "title": "BRIEF-Ironwood Pharmaceuticals Reports Q1 Loss Per Share Of $0.29",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " Ironwood Pharmaceuticals Reports Q1 Loss Per Share Of $0.29 Ironwood Pharmaceuticals Inc:\n* IRONWOOD PHARMACEUTICALS PROVIDES FIRST QUARTER 2018 INVESTOR UPDATE\n* Q1 NON-GAAP LOSS PER SHARE $0.27 * Q1 REVENUE $69 MILLION VERSUS I/B/E/S VIEW $79.1 MILLION\n* Q1 $-0.23 IW-3718 PHASE III PROGRAM EXPECTED TO INITIATE IN Q3 OF 2018\n* PHASE II SGC PROGRAMS, PRALICIGUAT AND OLINCIGUAT (IW-1701) CONTINUE TO PROGRESS\n* CO, ALLERGAN EXPECT TO INITIATE A SINGLE PHASE III TRIAL WITH LINZESS IN MID-2018\n* IRONWOOD - FOLLOWING SERIES OF MEETINGS WITH FDA, CO EXPECTS TO INITIATE 2 RANDOMIZED, PLACEBO-CONTROLLED PHASE III TRIALS FOR IW-3718 IN Q3 2018\n* ENDED Q1 2018 WITH ABOUT $194.4 MILLION CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE SECURITIES ",
    "published": "2018-05-01T15:00:00.000+03:00",
    "crawled": "2018-05-01T15:19:44.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "ironwood",
        "pharmaceutical",
        "report",
        "q1",
        "loss",
        "per",
        "share",
        "ironwood",
        "pharmaceutical",
        "inc",
        "ironwood",
        "pharmaceutical",
        "provides",
        "first",
        "quarter",
        "investor",
        "update",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "revenue",
        "million",
        "versus",
        "view",
        "million",
        "q1",
        "phase",
        "iii",
        "program",
        "expected",
        "initiate",
        "q3",
        "phase",
        "ii",
        "sgc",
        "program",
        "praliciguat",
        "olinciguat",
        "continue",
        "progress",
        "co",
        "allergan",
        "expect",
        "initiate",
        "single",
        "phase",
        "iii",
        "trial",
        "linzess",
        "ironwood",
        "following",
        "series",
        "meeting",
        "fda",
        "co",
        "expects",
        "initiate",
        "randomized",
        "phase",
        "iii",
        "trial",
        "q3",
        "ended",
        "q1",
        "million",
        "cash",
        "cash",
        "equivalent",
        "security"
    ]
}